new_0222_0670|CNTA|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0670|CNTA|Long Name|1|1|Centessa Pharmaceuticals PLC Total Current Assets (Quarterly) (USD)|Centessa Pharmaceuticals PLC Cash and Short Term Investments (Quarterly) (USD)|Centessa Pharmaceuticals PLC Inventories (Quarterly) (USD)|Centessa Pharmaceuticals PLC Net PP&E (Quarterly) (USD)|Centessa Pharmaceuticals PLC Goodwill and Intangibles (Quarterly) (USD)|Centessa Pharmaceuticals PLC Total Liabilities (Quarterly) (USD)|Centessa Pharmaceuticals PLC Total Current Liabilities (Quarterly) (USD)|Centessa Pharmaceuticals PLC Total Long Term Liabilities (Quarterly) (USD)|Centessa Pharmaceuticals PLC Total Deposits (Quarterly) (USD)|Centessa Pharmaceuticals PLC Book Value (Quarterly) (USD)|Centessa Pharmaceuticals PLC Retained Earnings (Quarterly) (USD)|Centessa Pharmaceuticals PLC Treasury Stock (Quarterly) (USD)|Centessa Pharmaceuticals PLC EV to Revenues|Centessa Pharmaceuticals PLC EV to Earnings|Centessa Pharmaceuticals PLC EV to Free Cash Flow|Centessa Pharmaceuticals PLC EV to Assets (Quarterly)|Centessa Pharmaceuticals PLC PS Ratio|Centessa Pharmaceuticals PLC PE Ratio|Centessa Pharmaceuticals PLC Price to Book Value|Centessa Pharmaceuticals PLC PEG Ratio|Centessa Pharmaceuticals PLC Debt to Equity Ratio|Centessa Pharmaceuticals PLC Dividend Yield|Centessa Pharmaceuticals PLC Shareholder Yield (TTM)|Centessa Pharmaceuticals PLC Percent of Shares Outstanding Short|Centessa Pharmaceuticals PLC Total Receivables (Quarterly) (USD)|Centessa Pharmaceuticals PLC Total Payables (Quarterly) (USD)|Centessa Pharmaceuticals PLC Total Capital Stock (Quarterly) (USD)|Centessa Pharmaceuticals PLC Return on Invested Capital|Centessa Pharmaceuticals PLC Quality Ratio Score|Centessa Pharmaceuticals PLC Momentum Score|Centessa Pharmaceuticals PLC Beta (1Y)|Centessa Pharmaceuticals PLC Sustainable Growth Rate (TTM)|Centessa Pharmaceuticals PLC Institutional Investor Ownership Percentage|Centessa Pharmaceuticals PLC Average Diluted Shares Outstanding (Quarterly)|Centessa Pharmaceuticals PLC Total Employees (Annual)|Centessa Pharmaceuticals PLC EPS Diluted (Quarterly) (USD)|Centessa Pharmaceuticals PLC SG&A Expense (Quarterly) (USD)|Centessa Pharmaceuticals PLC Shares Outstanding|Centessa Pharmaceuticals PLC Repurchase of Capital Stock (Quarterly) (USD)|Centessa Pharmaceuticals PLC Ordinary Shares Number (Quarterly)|Centessa Pharmaceuticals PLC Payout Ratio|Centessa Pharmaceuticals PLC Quick Ratio (Quarterly)|Centessa Pharmaceuticals PLC Normalized Diluted EPS (Quarterly) (USD)|Centessa Pharmaceuticals PLC Stock Buybacks (Quarterly) (USD)|Centessa Pharmaceuticals PLC Effective Tax Rate (TTM)|Centessa Pharmaceuticals PLC Return on Equity|Centessa Pharmaceuticals PLC Net Income (TTM) (USD)|Centessa Pharmaceuticals PLC Revenue (TTM) (USD)|Centessa Pharmaceuticals PLC Dividend Per Share (Quarterly) (USD)|Centessa Pharmaceuticals PLC Revenue (Quarterly) (USD)|Centessa Pharmaceuticals PLC Gross Profit (Quarterly) (USD)|Centessa Pharmaceuticals PLC Pre-Tax Income (Quarterly) (USD)|Centessa Pharmaceuticals PLC Net Income (Quarterly) (USD)|Centessa Pharmaceuticals PLC Net Interest Income (Quarterly) (USD)|Centessa Pharmaceuticals PLC Price (USD)|Centessa Pharmaceuticals PLC Total Return Price (USD)|Centessa Pharmaceuticals PLC Enterprise Value (USD)|Centessa Pharmaceuticals PLC 30-Day Average Daily Volume|Centessa Pharmaceuticals PLC 1 Year Price Returns (Daily)|Centessa Pharmaceuticals PLC Short Interest|Centessa Pharmaceuticals PLC PE Ratio (Forward)|Centessa Pharmaceuticals PLC PE Ratio (Forward 1y)|Centessa Pharmaceuticals PLC PS Ratio (Forward)|Centessa Pharmaceuticals PLC PS Ratio (Forward 1y)|Centessa Pharmaceuticals PLC Quarterly EPS Estimates (USD)|Centessa Pharmaceuticals PLC Quarterly Revenue Estimates (USD)|Centessa Pharmaceuticals PLC Quarterly EPS Surprise|Centessa Pharmaceuticals PLC Quarterly Revenue Surprise|Centessa Pharmaceuticals PLC Quarterly Actual EPS (USD)|Centessa Pharmaceuticals PLC Quarterly Actual Revenue (USD)|Centessa Pharmaceuticals PLC Revenue Estimates for Current Fiscal Year (USD)|Centessa Pharmaceuticals PLC Revenue Estimates for Next Fiscal Year (USD)|Centessa Pharmaceuticals PLC Price Target (USD)|Centessa Pharmaceuticals PLC Consensus Recommendation|Centessa Pharmaceuticals PLC Price Target Num Estimates|Centessa Pharmaceuticals PLC EPS Estimates for Current Fiscal Year (USD)|Centessa Pharmaceuticals PLC EPS Estimates for Next Fiscal Year (USD)|Centessa Pharmaceuticals PLC Research and Development Expense (Quarterly) (USD)|Centessa Pharmaceuticals PLC Reconciled Depreciation (Quarterly) (USD)|Centessa Pharmaceuticals PLC Non-Operating Interest Expense (Quarterly) (USD)|Centessa Pharmaceuticals PLC Land and Improvements (Quarterly) (USD)|Centessa Pharmaceuticals PLC Buildings and Improvements (Quarterly) (USD)|Centessa Pharmaceuticals PLC Other Properties (Quarterly) (USD)|Centessa Pharmaceuticals PLC Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0670|CNTA|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0670|CNTA||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0670|CNTA||5|5|91.5|91.5|0|91.5|0|91.5|91.5|91.5|0|91.5|91.5|0|0|0|0|0|0|0|1.44565217391|0|0|1.44565217391|0|15.5|91.5|91.5|91.5|0|0|0|0|0|30.625|92|0|92|92|21.875|0|91.5|0|0|92|0|0|0|0|0|0|0|0|92|92|92|1.44565217391|1.44565217391|1.44565217391|1.42580645161|0|15.5|0|0|0|0|91.4|92|92|0|92|92|146|146|29.25|23.4|29.25|29.25|29.25|92|0|92|0|0|0|0
new_0222_0670|CNTA||6|6|2|2|0|2|0|2|2|2|0|2|2|0|0|0|0|0|0|0|184|0|0|184|0|16|2|2|2|0|0|0|0|0|8|1|0|1|1|8|0|2|0|0|1|0|0|0|0|0|0|0|0|1|1|1|184|184|184|155|0|16|0|0|0|0|5|2|1|0|1|1|1|1|8|10|8|8|8|1|0|1|0|0|0|0
new_0222_0670|CNTA||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0670|CNTA|202103|202103|202103|313.636|298.612||0.045||41.886|18.977|22.909||30.787|-243.273||||||||||||||12.954|12.216|247.98|||||||||||||85.9244||||||||||||||||||||||||||||||||||||||||||||
new_0222_0670|CNTA|202105|202103|202103|||||||||||||||||||61.7625|||0||0|||||||||0.9364|||||87.4244|||||||||||||||||21.75|21.75|1851.0067|||0||||||||||||||||||||||||
new_0222_0670|CNTA|202106|202106|202106|643.682|613.759||0.075||58.115|24.185|33.93||585.642|-284.724||||||||3.4094|||0||0.9031|15.304|7.261|0.252||||||62.649|63.5167||-0.65|11.841|89.8994||89.8994|||-0.4719|||||||||-41.451|-41.451|0.027|22.21|22.21|1382.9067|||811894|||||-0.5933|0|-9.5512||-0.65|0|0|0|38|1.6667|3|-2.2933|-2.74|18.134||0||||
new_0222_0670|CNTA|202107|202106|202106|||||||||||||||||||3.1684|||0||0.8298|||||||||62.3475||||||||||||||||||||||20.64|20.64|1241.7646|208929.0667||745990||||||||||||||||||||||||
new_0222_0670|CNTA|202108|202106|202106|||||||||||||||||||3.3848|||0||0.8713|||||||||62.1933|||||89.8994|||||||||||||||||22.05|22.05|1368.5228|124098.1||783299|||||||||||||38|1.6667|3|-2.2233|-2.8933|||||||
new_0222_0670|CNTA|202109|202109|202109|611.645|578.815||0.114||63.074|29.144|33.93||549.133|-324.879||||||||2.734|||0||1.3086|21.556|18.456|0.252||||||72.552|89.8995||-0.45|12.464|89.9004|-0.012|89.9004|||-0.45|-344.124||||||||-40.155|-40.155|0.065|16.7|16.7|922.5217|116191.8667||1176397|||||-0.5533|0|18.6742||-0.45|0|||38.6667|1.6667|3|-2.2233|-2.8933|25.85||0||||
new_0222_0670|CNTA|202110|202109|202109|||||||||||||||||||2.8159|||0||1.7338|||||||||71.7653||||||||||||||||||||||17.2|17.2|967.4719|220119.4667||1558733||||||||||||||1.6667|||-2.89|||||||
new_0222_0670|CNTA|202111|202109|202109|||||||||||||||||||1.94|||0||2.3357|||||||||71.6734|||||89.9009|||||||||||||||||11.85|11.85|486.5107|198133.2333||2099845|||||||||||0|0|38.6667|1.6667|3|-2.05|-2.8867|||||||
new_0222_0670|CNTA|202112|202112|202112|||||||||||||||||||1.8434|||0||2.457|||||||||71.7064||||||||||||||||||||||11.26|11.26|433.4691|191380.4333||2208879|||||-0.5967|0|||||||38.6667|1.6667|3|-2.0333||||||||
new_0222_0670|CNTA|202201|202112|202112|||||||||||||||||||1.5602|||0||3.5791|||||||||71.5331||||||||||||||||||||||9.53|9.53|277.9406|200803.5||3217669|||||||||||||33|1.6667|3|-2.8867|-3.1|||||||
new_0222_0670|CNTA|202202|202112|202112|||||||||||||||||||1.4947|||0|||||||||||||||||||||||||||||||||9.13|9.13|241.9802|171121.5|||||||||||||||23|2|3|-3.0333|-3.0467|||||||
new_0222_0670|CNTA|202203|202203|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.7|||||||||||||||||||
new_0222_0670|CNTA|202206|202206|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.88|||||||||||||||||||
new_0222_0670|CNTA|202209|202209|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.08|||||||||||||||||||